Annovis Bio ($ANVS) partners with Weave Bio to use AI in preparing its NDA for buntanetap, targeting Alzheimer's and Parkinson's. Phase 3 enrollment hit 862 patients, topping the 760 target. Data expected March 2027. #Biotech #Alzheimers

Unbuzzd Wellness names Michael 'Zappy' Zapolin as CEO with a mandate to take the company public and launch a nationwide rollout of its hangover-relief beverage, unbuzzd(TM). Parent licensor Quantum BioPharma (NASDAQ: QNTM) stands to benefit via royalty agreements. #Biotech #IPO

VERAXA Biotech (NASDAQ: VRXA) is advancing its oncology pipeline and securing industry partnerships after its Nasdaq debut. Parent company Xlife Sciences reports strong H1 progress across a portfolio backed by 416 patents. #Biotech #Oncology

VERAXA Biotech (NASDAQ: VRXA) is advancing its oncology pipeline and securing industry partnerships after its June 2026 Nasdaq debut. Parent Xlife Sciences reports H1 portfolio progress across diagnostics, AI, and pharma, backed by 416 patents. #Oncology #Biotech

NanoViricides $NNVC has begun patient enrollment in its Phase II trial of NV-387 Oral Gummies for Ebola treatment in the Democratic Republic of Congo, marking a key clinical milestone for the nanomedicine company. #Ebola #Biotech

Regentis Biomaterials' GelrinC implant shows ~100% greater KOOS improvement vs. microfracture at 2 years, as orthopedics shifts from pain management to structural cartilage repair. CE Mark approved; U.S. trial enrollment targets year-end 2026. #Orthopedics #BioTech

Regentis Biomaterials' GelrinC hydrogel implant showed ~100% greater KOOS improvement vs. microfracture at 2 years. CE Mark approved in Europe, U.S. pivotal trial enrollment targeted for completion by end of 2026. Structural knee repair is gaining momentum. #Orthopedics #Biotech

Helix BioPharma appoints four senior leaders to its Board, including a new Chair, as part of a major governance overhaul designed to accelerate its oncology pipeline and long-term growth strategy. #Biotech #Oncology

Oncotelic Therapeutics (OTCQB: OTLC) opens BIO REBOOT registration for its AI-powered PDAOAI drug discovery platform, offering selected projects startup funding and full development support. Two keynote presentations confirmed for Drug Discovery 2026 in Burlingame, CA. #DrugDiscovery #Biotech

NanoViricides (NYSE: NNVC) will present at the NIBA 153rd Investment Conference Oct. 7, 2026. Their lead drug NV-387 is in Phase 2 trials for Ebola and Mpox, with FDA designations for measles treatment. A pipeline worth watching. #Biotech #Antiviral

Telomir Pharmaceuticals (NASDAQ: TELO) raises ~$5.6M in PIPE financing to fund its FDA-cleared Phase 1/2 trial of Telomir-Zn in triple-negative breast cancer. Major shareholder John Paul DeJoria contributed $1M to the raise. #Biotech #Oncology

Okogen receives India's CDSCO authorization to advance the EMERALD Phase 1/2 trial of Treyegen (OKG-0303), a novel single therapy targeting both viral and bacterial acute infectious conjunctivitis. Data expected later this year. #Biotech #Ophthalmology

Lantern Pharma (NASDAQ: LTRN) announces a $4M registered direct offering at $1.09/share, with warrants that could unlock an additional $4M. Proceeds will fuel its AI-driven oncology pipeline. #Biotech #Oncology

NanoViricides (NNVC) launches Phase II trials for NV-387 targeting Mpox and Ebola in the DRC, while securing FDA Orphan Drug and Rare Pediatric Disease designations for measles treatment. The company raised over $12M to fuel its growing antiviral pipeline. #Biotech #Antiviral